Alexander Spira, MD, PhD, FACP

Articles

Looking Toward the Future Management of Non–Small Cell Lung Cancer

August 16th 2022

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations

August 16th 2022

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Novel Therapy for NSCLC With ALK Rearrangements

August 9th 2022

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Novel Therapy for NSCLC With KRAS G12C Mutation

August 9th 2022

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Dr. Spira on the Further Investigations of Lazertinib/Amivantamab in EGFR-Mutant NSCLC

August 8th 2022

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

ADCs in NSCLC: Audience Q&A

August 8th 2022

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.

Dr. Spira on the Evaluation of Tusamitamab Ravtansine Plus Pembrolizumab in NSCLC

August 3rd 2022

Alexander I. Spira, MD, PhD, FACP, discusses the exploration of the antibody-drug conjugate tusamitamab ravtansine with pembrolizumab in patients with non–small cell lung cancer.

The Impact of ADCs on Non-Small Cell Lung Cancer Treatment

August 2nd 2022

A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.

Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation

August 2nd 2022

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?

August 2nd 2022

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Selecting Therapy for Advanced NSCLC With EGFR Mutations

July 26th 2022

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Neoadjuvant Strategies in Resectable Non–Small Cell Lung Cancer

July 26th 2022

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

ADCs in Non-Small Cell Lung Cancer

July 21st 2022

Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.

Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS Trials

July 19th 2022

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial

July 19th 2022

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

ADC Technology and Mechanism of Action

July 13th 2022

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.

Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC

July 12th 2022

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy

July 12th 2022

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy

July 5th 2022

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer

July 5th 2022

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.